XOStem is a stem cell biotechnology platform that develops therapies for Type 1 diabetes through the creation of engineered exosomes. This technology aims to restore insulin production and improve glycemic control in patients with this autoimmune condition.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Type 1 diabetes is an autoimmune condition where the body's immune system destroys insulin-producing beta cells in the pancreas, leading to insulin deficiency and impaired glycemic control. Current treatments, such as insulin injections or pumps, manage blood sugar levels but do not address the underlying autoimmune attack or restore native insulin production.
Solution
XOStem is developing engineered exosomes as a therapeutic modality for Type 1 diabetes. The platform aims to modulate the immune system and promote the regeneration of functional beta cells. By delivering targeted signals via exosomes, the therapy seeks to re-establish insulin production and improve glycemic control, potentially reducing or eliminating the need for exogenous insulin.
Target Audience
The primary target audience is individuals diagnosed with Type 1 diabetes who are seeking alternative or complementary therapies to manage their condition and potentially restore insulin production.
Features
- Engineered exosomes designed to deliver immunomodulatory signals
- Targeted delivery to pancreatic tissue to promote beta cell regeneration
- Potential to restore native insulin production
- Aims to improve glycemic control and reduce reliance on insulin therapy